FDA grants accelerated approval for Leqembi
Alzheimer’s drug Leqembi has been accepted via the US Food and Drug Administration (FDA)’s Accelerated Approval pathway.
Stay updated with breaking news from Billy Dunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alzheimer’s drug Leqembi has been accepted via the US Food and Drug Administration (FDA)’s Accelerated Approval pathway.
The US Food and Drug Administration (FDA) on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.
Washington: The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in...
The FDA has approved the new Alzheimer’s disease drug Leqembi (lecanemab-irmb) for clinical use in patients with early disease.
The FDA granted accelerated approval to Lecanemab — an experimental drug that will be marketed as Leqembi and likely spark considerable interest from patients and physicians across the country.